MedTrace Logo

Pulmonary Involvement in Patients With Fabry Disease

NCT01632111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2014-05-28

No results posted yet for this study

Summary

The objective of this study is to investigate whether Agalsidase alpha, a drug commonly prescribed in patients with Fabry disease, is associated with improvement of the pulmonary involvement. According to the Global Initiative for Obstructive Lung Disease (GOLD), the surrogate markers for obstructive lung diseases are a decrease in both forced expiratory volume in one second (FEV1) and FEV1/FVC ratio, whereas FVC is the forced vital capacity. However, the measurement of these lung function parameters is indicated as yearly follow-up examinations with or without the treatment of Agalsidase alpha in patients with Fabry disease.

Conditions

Interventions

OTHER

Lung function measurement

Spirometry

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Daniel Franzen, MD · University Hospital Zurich, Division of Internal Medicine

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632111 on ClinicalTrials.gov